MX352118B - Metodo de inmunoanalisis cromatografico multiplexado para la caracterizacion de inmunocomplejos circulantes. - Google Patents

Metodo de inmunoanalisis cromatografico multiplexado para la caracterizacion de inmunocomplejos circulantes.

Info

Publication number
MX352118B
MX352118B MX2014010318A MX2014010318A MX352118B MX 352118 B MX352118 B MX 352118B MX 2014010318 A MX2014010318 A MX 2014010318A MX 2014010318 A MX2014010318 A MX 2014010318A MX 352118 B MX352118 B MX 352118B
Authority
MX
Mexico
Prior art keywords
determining
immune
immune complexes
reported
size
Prior art date
Application number
MX2014010318A
Other languages
English (en)
Other versions
MX2014010318A (es
Inventor
Dahl Uwe
Jordan Gregor
Staack Roland
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2014010318A publication Critical patent/MX2014010318A/es
Publication of MX352118B publication Critical patent/MX352118B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)

Abstract

La presente invención se refiere a un método para terminar el tamaño de un anticuerpo anti-fármaco complejado con un fármaco polipéptido terapéutico exógeno (complejo ADA-D) que comprende una cromatografía por exclusión de tamaño, de una muestra obtenida de un mamífero al cual se le ha administrado el fármaco al menos una vez para determinar el peso/tamaño de los inmunocomplejos, opcionalmente una segunda cromatografía diferente a la SEC, y al menos un inmunoanálisis, por medio de esto el complejo inmune se caracteriza por la correlación del tamaño del complejo inmune y el resultado/lectura del inmunoanálisis.
MX2014010318A 2012-03-08 2013-03-07 Metodo de inmunoanalisis cromatografico multiplexado para la caracterizacion de inmunocomplejos circulantes. MX352118B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12158634 2012-03-08
PCT/EP2013/054587 WO2013132000A1 (en) 2012-03-08 2013-03-07 Multiplexed chromatography-immunoassay method for the characterization of circulating immune complexes

Publications (2)

Publication Number Publication Date
MX2014010318A MX2014010318A (es) 2014-09-22
MX352118B true MX352118B (es) 2017-11-09

Family

ID=47833082

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014010318A MX352118B (es) 2012-03-08 2013-03-07 Metodo de inmunoanalisis cromatografico multiplexado para la caracterizacion de inmunocomplejos circulantes.

Country Status (9)

Country Link
US (1) US9797900B2 (es)
EP (1) EP2823310B1 (es)
JP (1) JP6272788B2 (es)
KR (1) KR102084805B1 (es)
CN (1) CN104136923B (es)
CA (1) CA2862824A1 (es)
MX (1) MX352118B (es)
RU (1) RU2638812C2 (es)
WO (1) WO2013132000A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150039769A (ko) 2012-08-08 2015-04-13 에프. 호프만-라 로슈 아게 용액 중 결합 동역학의 면역검정-기반 측정
US20160334412A1 (en) * 2013-12-20 2016-11-17 Phadia Ab Analysis of antibodies
DK3105592T3 (en) * 2014-02-11 2019-02-04 Genzyme Corp PROCEDURES FOR DETERMINING THE PRESENCE OR THE QUANTITY OF AN ANTI-MEDICINE ANTIBODY
DE112019007232B4 (de) * 2019-05-20 2023-05-25 Mitsubishi Electric Corporation Zustandsschätzvorrichtung und zustandsschätzverfahren

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5238808A (en) 1984-10-31 1993-08-24 Igen, Inc. Luminescent metal chelate labels and means for detection
US5084398A (en) * 1987-11-20 1992-01-28 Creative Biomolecules Selective removal of immune complexes
ZA898290B (en) 1988-11-03 1991-06-26 Igen Inc Electrochemiluminescent assays
US5068088A (en) 1988-11-03 1991-11-26 Igen, Inc. Method and apparatus for conducting electrochemiluminescent measurements
IL100866A (en) 1991-02-06 1995-10-31 Igen Inc Method and apparatus for magnetic microparticulate based luminescence assay including plurality of magnets
DE19522171C1 (de) 1995-06-19 1996-08-22 Brahms Diagnostica Gmbh Verfahren zur Bestimmung von Anti-TSH-Rezeptor-Autoantikörpern
KR100950635B1 (ko) 2004-12-23 2010-04-01 에프. 호프만-라 로슈 아게 실험동물의 치료용 항체의 검출
WO2008031532A1 (en) 2006-09-12 2008-03-20 F. Hoffmann-La Roche Ag Anti-drug antibody assay
CN101506659B (zh) * 2006-09-12 2012-12-12 弗·哈夫曼-拉罗切有限公司 抗药物抗体测定法
WO2009140242A1 (en) * 2008-05-13 2009-11-19 Genentech, Inc. Analysis of antibody drug conjugates by bead-based affinity capture and mass spectrometry
MX2012004877A (es) * 2009-10-26 2012-05-23 Prometheus Lab Inc Analisis para la deteccion de farmacos anti-tnf y autoanticuerpos.
EP2354792A1 (en) 2010-02-08 2011-08-10 Biomonitor A/S Method for detecting anti-drug antibodies
SG189391A1 (en) * 2010-10-18 2013-05-31 Nestec Sa Methods for determining anti-drug antibody isotypes

Also Published As

Publication number Publication date
KR102084805B1 (ko) 2020-03-04
RU2014140135A (ru) 2016-04-27
HK1199103A1 (zh) 2015-06-19
KR20140132360A (ko) 2014-11-17
US9797900B2 (en) 2017-10-24
EP2823310A1 (en) 2015-01-14
CN104136923A (zh) 2014-11-05
EP2823310B1 (en) 2018-06-20
CN104136923B (zh) 2016-08-24
RU2638812C2 (ru) 2017-12-15
MX2014010318A (es) 2014-09-22
US20150132781A1 (en) 2015-05-14
JP6272788B2 (ja) 2018-01-31
WO2013132000A1 (en) 2013-09-12
JP2015509598A (ja) 2015-03-30
CA2862824A1 (en) 2013-09-12

Similar Documents

Publication Publication Date Title
AR125268A2 (es) Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
CO6351801A2 (es) Anticuerpos neutralizantes de citomegalovirus humano y uso de los mismos
MX2012006406A (es) Anticuerpos multiespecificos, analogos de anticuerpo, composiciones y metodos.
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
MX2014016014A (es) Metodos para determinar eficacia de farmacos usando proteinas asociadas a cereblon.
EA201590247A1 (ru) Антитела к siglec-15
EA201491977A1 (ru) Молекула антитела к gcc и ее применение для тестирования на чувствительность к gcc-нацеленной терапии
BRPI1012340A8 (pt) proteínas de ligação específica e usos das mesmas
BR112014016299A8 (pt) imunoglobulinas de domínio variável e usos das mesmas
BR112014026531A2 (pt) proteínas de ligação de antígeno ligando cd30 humano
EA201591423A1 (ru) Введение антитела к активину-а пациентам
PH12020550598A1 (en) Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells
EA201301107A1 (ru) Моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
MX352118B (es) Metodo de inmunoanalisis cromatografico multiplexado para la caracterizacion de inmunocomplejos circulantes.
CA2888908A1 (en) Antibodies against kidney associated antigen 1 and antigen binding fragments thereof
ES2543850A2 (es) Uso de complejos metálicos miméticos de SOD como agentes alimentarios y como cosméticos
BR112014000908A2 (pt) composto, composição farmacêutica e respectivos usos e métodos para tratar hipogonadismo secundário ou distúrbio associado ao mesmo, infertilidade em mulher, diabetes do tipo 2 em humano do sexo masculino, câncer da mama em mulher e câncer do endomètrio, do ovàrio ou uterino em mulher, para prevenir a transição da síndrome metabólica para diabetes do tipo 2 em humano do sexo masculino e câncer da mama em mulher e para reduzir níveis de glicose no sangue em jejum de humano do sexo masculino
WO2013106766A3 (en) THERAPEUTIC INDICATIONS OF miR-1291
WO2014169011A3 (en) Methods for treating immune diseases
BR112015027249A2 (pt) método de diagnóstico de câncer
WO2011156740A3 (en) Diagnosis of myocardial autoimmunity in heart disease
UA86387U (ru) Способ оценки эффективности лечения больных с артериальной гипертензией, объединенной с метаболическим синдромом
Mohammad Hossein et al. Evaluation of cardiac systolic and diastolic function by echocardiographic tei index in thalassemic patients referring to hazrate masoumeh hospital, Qom, Iran, 2012-2013
赵敬柱 Prediction of early recurrence after radical resection for advanced gastric cancer
Lelonek Psoriasis: 2 case reports

Legal Events

Date Code Title Description
FG Grant or registration